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Abstract
Background:  Adjuvants are known to significantly enhance vaccine efficacy. However,
commercial adjuvants often have limited use because of toxicity in humans. The objective of this
study was to determine the comparative effectiveness of a diterpene alcohol, phytol and its
hydrogenated derivative PHIS-01, relative to incomplete Freund's adjuvant (IFA), a commonly used
adjuvant in augmenting protective immunity in mice against E. coli and S. aureus, and in terms of
inflammatory cytokines.
Methods: Vaccines, consisting of heat-attenuated E. coli or S. aureus and either of the two phytol-
based adjuvants or IFA, were tested in female BALB/c mice. The vaccines were administered
intraperitoneally at 10-day intervals. The efficacy of the phytol and PHIS-01, as compared to IFA,
was assessed by ELISA in terms of anti-bacterial antibody and inflammatory cytokines. We also
examined the ability of the vaccines to induce specific protective immunity by challenging mice with
different doses of live bacteria.
Results and discussion: IFA, phytol, and PHIS-01 were equally efficient in evoking anti-E. coli
antibody response and in providing protective immunity against live E. coli challenges. In contrast,
the antibody response to S. aureus was significant when PHIS-01 was used as the adjuvant.
However, in terms of the ability to induce protective immunity, phytol was most effective against
S. aureus. Moreover, during challenges with live E. coli and S. aureus immune mice produced much
less IL-6, the mediators of fatal septic shock syndromes.
Conclusion:  Our results show that vaccine formulations containing phytol and PHIS-01 as
adjuvants confer a robust and protective immunity against both Gram-negative and Gram-positive
bacteria without inducing adverse inflammatory cytokine due to IL-6.
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Background
Protective immunity in vertebrates depends largely on
efficient activation and subsequent interactions of cells
belonging to both innate and acquired immunity. The
innate component, however, has no memory and is first
to respond with only a limited repertoire to recognize
pathogen-associated molecular patterns (PAMPs), usually
present in the cell wall structures of microbes [1-3].
PAMPs function as immunoadjuvants or immunostimu-
lants and up-regulate TOLL-like receptors of cells belong-
ing to innate immunity that in turn activates the specific
acquired immunity. [4,5]. The activation of specific
immunity mediated by B and T lymphocytes requires at
least 3–4 days, but it lasts much longer and responds spe-
cifically to a diverse range of microbial antigens [6,7].
Therefore, vaccines that interact with both components of
the immune system have the ability to induce effective
prophylaxis against a variety of infectious diseases.
In bacterial infection, antibody response is crucial for neu-
tralizing bacterial toxins or blocking their attachment to
host cells [8]. Antibodies also help recruit complement to
kill and dispose of organisms, as well as enhance the bind-
ing and uptake by phagocytes [9]. Most anti-microbial
vaccines in current use have been designed to stimulate
antibody responses, and the development of effective cell-
mediated immunity is also important to overcome
chronic infectious diseases associated with intracellular
pathogens and viruses [10]. In spite of historical successes
with killed or attenuated microbes as vaccines, the loom-
ing threat of new and resistant pathogens requires devel-
opment of new and improved versions of vaccines.
Molecular vaccines produced by modern technology (e.g.
synthetic peptides, DNA vaccines) are safer than tradi-
tional vaccines composed of inactivated or killed organ-
isms [11]. Because of a relatively limited antigenic
repertoire, molecular vaccines are often poorly immuno-
genic and depend on the co-administration of immunos-
timulants or adjuvants to be effective. Therefore, there is a
constant need to develop new adjuvants that are 1) safe
for clinical use; 2) able to enhance immunogenicity of
vaccine proper; and 3) likely to improve the performance
of both traditional and molecularly defined vaccines.
Unlike the vaccine itself, which is often restricted in action
to specific and cross-reactive antigens, adjuvants have
much wider usage as immunostimulants with many dif-
ferent vaccines. In our ongoing study [12], we have
observed that phytol, an aliphatic alcohol component of
chlorophyll, and its derivative, PHIS-01, are excellent
adjuvants, superior in many respects to commonly used
and commercially available standard adjuvants (Com-
plete/Incomplete Freund's adjuvant, Alum, Titermax, and
Ribi adjuvant system). Unlike the conventional adjuvants,
these phytol-based adjuvants are safe with high benefit-
to-toxicity ratio, generate more IgG2a-type complement-
fixing antibodies, and trigger no lupus-like syndromes in
susceptible mice [12]. They also augment cytotoxic T cell
response (CTLs) directed toward a murine B-cell lym-
phoma [12].
This study was initiated to determine the effectiveness of
phytol-based adjuvants against commonly occurring
gram-negative and gram-positive bacteria. Escherichia coli
and Staphylococcus aureus are prevalent pathogens associ-
ated with nosocomial and community-acquired infec-
tions of various body sites and disease processes [13,14].
We report here that phytol-based adjuvants enhance the
immune responses to E. coli and S. aureus infections better
than IFA, the commonly used commercial adjuvant with
fewer side effects. Phytol-based adjuvants influence many
parameters of immune response including its intensity,
duration, isotype and specificity. Furthermore, immuniza-
tions in mice using whole, inactivated bacterial cells plus
the phytol adjuvants provide a lasting protection against
intraperitoneal challenge with high doses of live E. coli.
Equally effective are heat-attenuated S. aureus vaccines
plus phytol adjuvants, which produce excellent antibody
response and lasting immunity to S. aureus challenge.
Methods
Bacterial culture
Bacteria,  E. coli (ATCC number: 14948) and S. aureus
(ATCC number: 25935,) kindly provided by Dr. H. K.
Dannelly of the Department of Life Sciences), were cul-
tured in LB broth (Difco, Detroit, MI) at 37°C for 14
hours and harvested with phosphate buffered saline
(PBS). Cells were washed in PBS by centrifugation at 500
× g for 10 min at 4°C and then suspended to the appro-
priate density in PBS. Bacteria were killed by heating sus-
pensions to 60°C for 1 hr.
Preparation of immunogen
Test vaccines consisted of either 5 × 106 CFU of E. coli or
S. aureus and various adjuvants in a total volume of 400
µl. Adjuvants used in this study include: IFA (Sigma
Chemical Co., St. Louis, MO), phytol (Pfaltz and Bauer
Inc., Waterbury, CT) and PHIS-01 (Patent pending).
PHIS-01 is one of several chemically modified phytol-
based adjuvants developed in this laboratory.
Mice-immunization and challenge
Female BALB/c mice (6–8 weeks of age) were used for all
experiments. These mice were bred and maintained at the
animal care facility of Indiana State University. The use of
these mice has been guided by strict adherence to an
approved protocol prepared under the supervision and
oversight of the Indiana State University Animal Care and
Use Committee.Journal of Immune Based Therapies and Vaccines 2006, 4:5 http://www.jibtherapies.com/content/4/1/5
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Immunization was carried out in groups of 4–5 mice
using either 5 × 106 CFU of E. coli or S. aureus and test
adjuvants (IFA, Phytol, or PHIS-01) in a total volume of
400 µL. Bacteria without adjuvant in a total volume of 400
µL PBS were used as control. Vaccines were administered
intraperitoneally (I.P.) and animals were immunized
three times at 10-day intervals. Sera were collected 5–7
days after each immunization for analysis by ELISA.
For the protection assay, mice were challenged with an IP
injection of E. coli or S. aureus (106, 107, and 108 CFU/
mouse) in 1.0 ml of PBS. Challenges took place on day 5
after the third immunization.
Preparation of bacterial cell lysates
Bacterial cultures were harvested and washed in PBS. Cells
were lysed in 1 ml of buffer containing 8 M urea, 0.01 M
Na-phosphate (dibasic), 0.01 M Tris-HCl (pH 8.0), and 5
µl of protease inhibitor cocktail. Cell debris was removed
by centrifugation at 13,000 × g for 5 min at 4°C. Superna-
tant was collected and protein concentration was esti-
mated from absorbance at 280 nm. Adopting a procedure
reported by Gomez et al. [6], these lysates were used to
coat 96-well microtiter plates for ELISA.
Enzyme-Linked Immunosorbent Assay (ELISA)
Antibody levels of mouse sera were measured routinely by
a binding assay to antigen-coated ELISA plates:
(a) Antibody specific to bacterial strain: Cell-lysate coated
ELISA plates were prepared by incubating polyvinyl 96-
well plates with 10 µg/ml cell lysates in 0.01 M sodium
bicarbonate solution overnight at 4°C. After blocking
with 1% BSA/PBS overnight at 4°C, serially diluted sera
obtained from immunized mice were added to each well,
and incubated for 1 hr at 37°C. Plates were incubated
with rabbit anti-mouse Ig-HRP and washed. Bound rabbit
anti-mouse Ig-HRP was detected by addition of o-phe-
nylene diamine (OPD), and the intensity was measured at
490 nm. Specific IgG antibodies were expressed as the
mean ± SEM.
(b) Antibody specific to LPS: LPS (Sigma Chemical Co., St.
Louis, MO) suspended in PBS were placed in poly-L-lysine
(Sigma, St. Louis, MO) precoated ELISA plates and incu-
bated for 1 hr at 37°C. The plates were washed three times
with PBS containing 0.05% Triton-X, and ELISAs per-
formed using conditions described by Takahashi et al
[15].
Antibody-subclass determination
To determine the characteristics of antibody response
induced by vaccination, mouse immune sera were typed
for IgM, IgG1, IgG2a, IgG2b, and IgG3 classes using anti-
mouse Ig subclass-specific HRP-conjugated secondary
antibodies (Zymed, San Francisco, CA), following the
manufacturer's protocol. The ratio of IgG1 and IgG2a iso-
types was calculated by dividing the A405 values for IgG1
by IgG2a.
SDS-PAGE and Western blot
Cell lysates, as described above, were mixed with an equal
volume of SDS-PAGE sample buffer (Bio-Rad Laborato-
ries, Hercules, CA) and electrophoresed on 12% polyacry-
lamide gels. The proteins were transferred to
nitrocellulose membranes and rabbit anti-mouse Ig (A +
M + G) (ICN, Irvine, CA) antibodiesand HRP-conjugated
goat anti-rabbit Ig (Sigma Chemical Co., St. Louis, MO)
were used to detect total Ig (M + G). HRP-conjugated rab-
bit anti-mouse IgG (Sigma Chemical Co., St. Louis, MO)
was used to detect specific IgG type antibodies. Color
development was accomplished using Supersignal®
chemiluminescent (Pierce, Rockford, IL).
Cytokine assays
Proinflammatory cytokines, IL-6 and TNF-α levels in
blood and peritoneal lavage were determined by ELISA.
ELISA was performed in triplicate using specific mAbs
(eBioscience, San Diego, CA) according to the manufac-
turer's instructions.
Monitoring of infection and mortality
These studies were conducted in PBS-treated control and
experimental mice in various groups. These mice were
vaccinated with killed bacterial lysates in the presence or
absence of adjuvants. Animal mortality was assessed every
12 h during the first 3 days following bacterial challenges
(106, 107 or 108 CFU/mouse) and peritoneal fluid and
blood were cultured to confirm infection. Mortality
occurred predominantly between 12 h and 36 h after chal-
lenge. At 18 h after bacterial challenge, blood and perito-
neal lavages were obtained for quantitative culturing.
Samples from all groups of mice were diluted in LB
medium (1:200), and a 10 µl sample of each of these was
streaked on agar plates using calibrated loops to detect
bacteremia caused by >103 CFU/ml.
Statistical analysis
Statistical analyses of all data were done by the paired Stu-
dent's t-test (Sigma Plot). For all statistical tests, alpha was
set at 0.05. All data were expressed as mean ± SEM in the
figures and tables.
Results
Specific anti-bacterial antibody responses
Sera of immunized mice collected over the course of three
immunizations were analyzed by ELISA to determine the
induction and duration of antibody response. Low but
detectable serum antibodies specific for E. coli were found
at comparable levels in all mice immunized with adju-Journal of Immune Based Therapies and Vaccines 2006, 4:5 http://www.jibtherapies.com/content/4/1/5
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vants after the second immunization. However, compared
to mice immunized with E. coli alone (in PBS), those
immunized with IFA, phytol, and PHIS-01 registered sig-
nificantly high antibody levels (n = 5, P < 0.05) after the
3rd immunization (Fig 1A). By contrast, in the case of S.
aureus-immunized mice, only phytol, but not IFA or
PHIS-01, engendered higher serum antibody response (n
= 5, P < 0.05) after the 3rd immunization (Figure 1B).
Efficacy of adjuvant in sustaining antibody response 
induced
The durability of antibody response elicited due to inclu-
sion of adjuvants in the vaccine was determined 30 and 60
days after the third immunization. Although all mice
receiving bacterial vaccines plus adjuvants evoked signifi-
cant antibody response, its durability depended on the
selection and inclusion of proper adjuvants. The results in
Fig. 2A and 2B show that there was no steep decline in
antibody level of mice immunized with either E. coli or S.
aureus over a period of almost three months. It is notewor-
thy that both PHIS-01 and phytol were as effective as the
standard adjuvant IFA in the case of E. coli, but for Gram-
positive S. aureus, only phytol was more effective in pro-
viding sustained anti-bacterial antibody response.
Isotype profile of strain-specific antibody
IgG subclasses not only have relatively longer half-lives,
they are also important in view of their specific effector
functions. Therefore, we determined antibody isotype
elicited in response to different vaccine formulations by
ELISA using commercial, calibrated class-specific anti-
Efficacy of adjuvants in sustaining antibody response induced Figure 2
Efficacy of adjuvants in sustaining antibody response induced. 
BALB/c mice in groups of 4 or more were immunized at day 
0, 10, 20 with bacterial vaccine in various adjuvants, and the 
antibody responses specific to either E. coli (A), or S. aureus 
(B) were determined by ELISA 30 and 60 days following the 
3rd immunization. Results are expressed as mean ± SEM.
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Antibody response in BALB/c mice following immunization  with bacterial vaccines prepared in test adjuvants Figure 1
Antibody response in BALB/c mice following immunization 
with bacterial vaccines prepared in test adjuvants. Control 
mice were either unimmunized or immunized with vaccines 
in PBS with no adjuvant. The ∆OD490 values were obtained 
by subtracting absorbance due to normal mouse sera from 
the experimental ones. Polyclonal antisera obtained from E. 
coli or S. aureus were evaluated at 1:200 dilutions by ELISA. 
The results represent the average of three separate experi-
ments (n = 4 mice in each three experiments) ± SEM. A. 
Anti-E. coli Ab response, B. Anti-S. aureus Ab response. Signif-
icant increase of antibody response was observed in the sera 
of mice after the third immunization (P < 0.05).
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sera. Whereas, the sera from mice immunized with E. coli
in IFA and phytol showed high concentrations of IgG1,
the IgG2a and IgG3 levels were higher only in PHIS-01-
treated mice (Fig 3A). Notably, the ratio of IgG2a to IgG1
was >2.5 times higher only in mice immunized with
PHIS-01 (Fig. 3B). In contrast, IgM was the predominant
isotype in mice immunized with S. aureus and IFA or
PHIS-01. However, only phytol and PHIS-01 elicited ele-
vated levels of IgG1 in response to vaccination with S.
aureus (Fig 3C).
Antigenic specificity of serum antibodies
Figure 4 shows western blot analysis of serum samples
obtained from mice immunized with heat-inactivated
bacteria (60°C for 1 hr in a water bath) in various adju-
vants. Antisera, used at 1:200 dilution during assay, recog-
nized in E. coli, a few antigens of molecular sizes ranging
from 40–100 KDa (Fig. 4A). The antisera in response to S.
aureus recognized proteins of 45, 74, 87, 90 and 95 KDa
(Fig 4B). It appears that anti-sera developed in response to
E. coli using IFA and PHIS-01 were stronger than those
obtained from mice immunized with phytol as adjuvant
(Fig. 4A).
Bacterial clearance from mice immunized with various 
adjuvants
Mice were challenged intraperitoneally with three doses
(106, 107, or 108 CFU) of viable E. coli and S. aureus. Bac-
terial growth was determined in the peritoneal lavages
harvested 18 and 36 hours after challenge with live bacte-
ria. It was observed that when the challenge dose of either
E. coli or S. aureus was 106 CFU, no bacteria was detectable
in the control or vaccinated mice suggesting that they were
eliminated by 36 hour from the blood streams and perito-
neal fluids (Table 1 and Table 2). However, if the PBS and
IFA-treated groups were infected with 107 CFU of E. coli, a
large number of the bacteria were detectable in the perito-
neal lavages even after 36 hours after the challenge, and
importantly, no mouse survived the challenge with 108
CFU of the bacteria (Table 1). A striking contrast is readily
apparent in the PHIS-01 or phytol-treated groups of mice
since mice in both cases had no detectable E. coli after 36
hr (Table 1).
In the case of S. aureus infection also, the challenges with
higher than 106 CFU caused a considerable number of the
bacteria to persist in the peritoneal fluids of mice treated
with PBS, IFA and PHIS-01. The unimmunized control
and the PBS-treated vaccinated groups succumbed to
infection and died within 36 hrs after challenge. The IFA
and PHIS-01 groups survived during this period and even-
tually the PHIS-01-treated mice survived. Most notewor-
thy, however, is the effect of Phytol, which registered no
bacterial detectable growth 36 hrs after challenge and
resisted infection most effectively (Table 2).
Isotypic profiles of humoral immune responses in mice  immunized with bacterial vaccine formulated in different  adjuvants Figure 3
Isotypic profiles of humoral immune responses in mice 
immunized with bacterial vaccine formulated in different 
adjuvants. Sera for this assay were diluted 1:200 prior to 
detection of each isotype. Results are expressed as mean ± 
SEM. A. Isotypic profiles of anti-E. coli antibodies. B. Relative 
levels of IgG1 and IgG2a anti-E. coli antibodies C. Isotypic pro-
files of anti-S. aureus antibodies
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Influence of adjuvants on survival from bacterial challenge
To examine whether adjuvants differ in effectiveness in
terms of animal survival, mice were inoculated with 106,
107, or 108 CFU per mouse of E. coli or S. aureus. As shown
in Figure 5 (A&B), mice immunized with 106 CFU of
either E. coli or S. aureus showed few symptoms and all
mice survived. However, mice challenged with larger inoc-
ula such as 107, or 108 CFU of either bacterium were
lethargic and suffered from loose stools. If death did not
occur within 24 hrs of bacterial challenge, the mice sur-
vived from the infection. Phytol and PHIS-01 were both
much more effective than PBS (i.e., vaccines with no adju-
vants) and IFA in conferring protection against E. coli.
Interestingly, the overall survival rate of mice immunized
with S. aureus was somewhat higher than in mice immu-
nized with E. coli. Mice vaccinated with S. aureus and phy-
tol showed the best protection against S. aureus challenge.
Effects of adjuvants on inflammatory cytokines (IL-6 and 
TNF-α)
In order to determine whether adjuvants exert any effects
on induction of inflammatory cytokines, such as IL-6 and/
or TNF-α, the levels of these cytokines were measured in
peritoneal lavages. The results obtained from mice chal-
lenged with 106 CFU of E. coli, or S. aureus are shown in
Fig. 6. Since bacterial inocula larger than 106 CFU killed
all control unimmunized mice within 24 hrs, these exper-
iments were performed using only 106 CFU of each bacte-
rium. There was no significant increase in the TNFα-level
in all groups of mice, whereas the IL-6-level was signifi-
cantly lower in phytol and PHIS-01-treated mice inocu-
lated with E. coli (Fig 6A). In contrast, there was much less
of either cytokine induced during the S. aureus challenge
(Fig 6B).
Discussion
There has been, to our knowledge, no prior systematic
investigation involving the efficacy of dietary isoprenoids,
Western blot analyses of antigens recognized in bacterial  lysates by mouse anti-sera induced with bacterial vaccine  prepared in various adjuvants Figure 4
Western blot analyses of antigens recognized in bacterial 
lysates by mouse anti-sera induced with bacterial vaccine 
prepared in various adjuvants. Lane 1: Molecular marker; 
Lane 2: PBS (vaccinated with no adjuvant); Lane 3: IFA; Lane 
4: PHIS-01; Lane 5: Phytol. Unimmunized controls or normal 
mouse sera revealed no protein recognizable by either 
antiserum. A. Antigens revealed by antisera from the E. coli-
vaccinated groups. B. Antigens revealed by antisera from the 
S. aureus -vaccinated groups.
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Table 1: Recovery of E. coli from peritoneal fluid obtained from mice challenged with live E. coli
Bacterial challenge 
(CFU)
106 107 108
Time 36 hrs post infection 18 hrs post infection 36 hrs post infection 18 hrs post infection 36 hrs post infection
1Control group (non-
immunized)
0 2N/A 2N/A 2N/A 2N/A
1PBS 0 3.2 ± 1.1 × 104 4.4 ± 1.2 × 1052 N/A 2N/A
1IFA 0 1.8 ± 0.5 × 104 6.0 ± 1.6 × 1042 N/A 2N/A
1PHIS-01 0 0 0 1.1 ± 0.1 × 104 0
1PHYTOL 0 0 0 2.1 ± 0.5 × 104 0
1 Peritoneal fluid samples from all groups of mice were diluted in LB medium (1:200), and 10 µl of diluted samples were streaked on agar plates 
using calibrated loops. CFUs were scored 18 and 36 hours following bacterial challenge and recorded as CFU/ml. The results represent the average 
of two experiments (n = 4 for each group) ± SEM. 2 N/A: Not assessable since all mice were dead within 18 hrs.Journal of Immune Based Therapies and Vaccines 2006, 4:5 http://www.jibtherapies.com/content/4/1/5
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such as phytol or phytol-derived compounds, as adju-
vants. In our ongoing study [12], we have tested the adju-
vant activity of phytol, and its reduced derivative, PHIS-
01, and observed efficient stimulation of antibody
response against hapten antigens conjugated to a protein
carrier. We have observed that the response due to these
adjuvants appeared superior to what has been observed
with conventional adjuvants, such as CFA/IFA, TiterMax,
and Alum. PHIS-01, in particular, also efficiently evokes
cellular immunity, including tumor-specific cytotoxic and
helper T cell responses [12]. In this report, we have
assessed the usefulness of the adjuvant potentials of phy-
tol and PHIS-01 in augmenting efficacy of vaccines
against the common infectious agents S. aureus and E. coli.
Our vaccine formulations contain heat-inactivated bacte-
ria emulsified with standard IFA, or either of the two
experimental phytol-based adjuvants. The latter, unlike
IFA, have been used without any emulsifying or surface-
active agents. In spite of these differences, these new adju-
vants are effective not only in augmenting anti-bacterial
humoral responses against both E. coli and S. aureus, but
also in preventing bacteremia and death caused by these
infections. Phytol and its derivative seem to be excellent
adjuvants for their ability to enhance and sustain quality
antibody responses (preventing bacteremia) over a longer
period of time. Thus, phytol-based novel adjuvants signif-
icantly improve vaccine efficacy by modulating immuno-
genicity and toxicity of the heat-killed bacterial inocula,
responsible for gram-negative bacteremia [16-18]. How-
ever, phytol and PHIS-01 adjuvants differ in their effec-
tiveness against gram-positive S. aureus. Phytol is better at
increasing specific antibody responses and preventing
bacteremia and death due to S. aureus.
It has been well known that IgG2a is the most desirable
antibody isotype for therapeutic applications involving
normal immune responses [19]. This isotype is more
effective in activating complement, promoting antibody-
dependent cellular cytotoxicity, and conferring protection
against tumors or parasite invasion than any other iso-
type. In mice immunized with E. coli, phytol and in par-
ticular, PHIS-01 exert their effects in raising mouse serum
levels of all major IgG subclasses, specifically IgG2a anti-
body. In contrast, mice vaccinated with S. aureus lysates
emulsified with phytol register higher levels of IgG1-type
antibody, and are better protected, whereas IFA and PHIS-
01 do not exert much effect on this isotype switch. Both
IFA and PHIS-01 promote induction primarily anti-staph
IgM response, which is not associated with the immuno-
logical memory. This induction of IgG1 antibody against
gram-positive S. aureus observed with phytol implicates
Th2-type cellular responses and the establishment of
immunological memory.
Adjuvants facilitate the persistence of antigens at injection
sites, the so-called depot effect. The qualitative differences
in adjuvant efficacy can also be gleaned from the analyses
of antigens involved in immune responses. The E. coli
antigens recognized by immune sera due to phytol and
PHIS-01 are clearly discernible on western blots as com-
pared to immune sera obtained from IFA-immunized
mice. A 45 KDa antigen was recognized by antibodies
from mice immunized with phytol and PHIS-01 only.
Similarly, IgG antibodies only from the phytol group rec-
ognized four unique S. aureus antigens (approximately
45, 74, 90 and 95 KDa). Our findings suggest that phytol
and PHIS-01 differ from the conventional adjuvant IFA in
their ability to augment the immunogenicity of bacterial
antigens. This may explain why phytol and its derivative
provide better protection against re-exposure to the path-
ogens. The biochemical nature of these antigens remains
to be elucidated.
The efficacy of phytol and PHIS-01 as adjuvants is also
evident in the quality of protection that the vaccines pro-
Table 2: Recovery of S. aureus from peritoneal fluid obtained from mice challegened with live S. aureus
Bacterial challenge 
(CFU)
106 107 108
Time 36 hrs post infection 18 hrs post infection 36 hrs post infection 18 hrs post infection 36 hrs post infection
Control group (non-
immunized)
0 1.08 ± 0.14 × 106 8.98 ± 1.94 × 106 1.11 ± 0.20 × 1082 N/A
PBS 0 4.92 ± 0.94 × 105 1.54 ± 0.94 × 106 3.16 ± 1.94 × 1062 N/A
IFA 0 2.35 ± 1.12 × 105 1.23 ± 1.14 × 106 1.80 ± 0.22 × 106 2.16 ± 1.10 × 106
PHIS-01 0 3.64 ± 1.44 × 105 1.13 ± 2.31 × 106 8.90 ± 3.20 × 105 5.60 ± 0.94 × 105
PHYTOL 0 4.0 ± 0.25 × 103 0 8.90 ± 1.12 × 104 0
1 Peritoneal fluid samples from all groups of mice were diluted in LB medium (1:200), and 10 µl of diluted samples were streaked on agar plates 
using calibrated loops. CFUs were scored 18 and 36 hours following bacterial challenge and recorded as CFU/ml. The results represent the average 
of two experiments (n = 4 for each group) ± SEM. 2 N/A: Not assessable since all mice were dead within 18 hrs.Journal of Immune Based Therapies and Vaccines 2006, 4:5 http://www.jibtherapies.com/content/4/1/5
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vide against infection from the early onset. In lethal cases,
a marked fall in antibody levels invariably increases the
probability of high mortality in mice [20]. Mice immu-
nized with killed E. coli and phytol or PHIS-01 showed
transient bacteremias and all survived. The state of immu-
nity was maintained even when mice were challenged
with 106 CFU of E. coli cells. These important results sug-
gest that the immunological memory against relevant
antigen(s) can facilitate rapid elimination of the infec-
tious agent from the blood streams and peritoneum. In
contrast, mice immunized with either PBS or IFA die
within 1–3 days.
Underlying mechanisms defining the differences in adju-
vanticity of phytol and PHIS-01 relative to IFA could
potentially lie in monocytes and macrophages that pro-
A. Survival from E. coli infection Figure 5
A. Survival from E. coli infection. B. Survival from S.aureus infection. Each group of ten mice immunized with bacterial vaccine 
formulated in various adjuvants was challenged with live bacteria (106, 107, and 108), and observed for survival.
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duce pro-inflammatory cytokines such as TNF-α and IL-6.
These cytokines play important roles as mediators of fatal
septic shock [22-25]. In our investigation, little TNF-α
could be detected at 18 hr after bacterial infection. How-
ever, IL-6 is detectable in peritoneal lavage and blood for
a short period in mice immunized with PBS and IFA, but
not phytol and PHIS-01. It is apparent from this study that
heat-inactivated microorganisms are not immunogenic
enough to induce an effective immune response, and that
adjuvants in vaccine formulations could make the differ-
ence. Our results demonstrate the usefulness of phytol
and PHIS-01 as effective adjuvants. Interestingly, mice
that survive bacterial infections produce less TNF-α and
Effect of adjuvants on proinflammatory cytokine production (IL-6 and TNF-α) in response to bacterial vaccine Figure 6
Effect of adjuvants on proinflammatory cytokine production (IL-6 and TNF-α) in response to bacterial vaccine. The levels of IL-
6 and TNF-α were determined by ELISA in peritoneal lavages obtained from mice immunized with bacterial vaccines followed 
by challenge with either live E. coli (A), or S. aureus (B).
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IL-6 cytokines, the important mediators of fatal septic
shock.
Thus, the development of muti-epitopic E. coli and  S.
aureus vaccines using these adjuvants appears promising.
The other area of interest is to develop anti-bacterial
gamma globulins for intravenous use preventing toxemic
episodes. It has previously been shown by Kaijser et al.
that the passive administration of a monoclonal Ab spe-
cific to E. coli in conjunction with an antibiotic signifi-
cantly improves the survival of animals with experimental
infection [26]. High-risk patients with poor host defense,
such as prematurely born infants and patients undergoing
immunosuppressive chemotherapy, may even benefit
from passive infusion of immune responses induced in
competent individuals. Since most fatal nosocomial infec-
tion is caused by E. coli and S. aureus, it will be of interest
to develop IgG-enriched vaccines for prophylaxis and for
the treatment of nosocomial sepsis.
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